Edesa Biotech (EDSA) to Release Earnings on Friday

Edesa Biotech (NASDAQ:EDSA) is expected to announce its results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Edesa Biotech (NASDAQ:EDSA) last released its earnings results on Friday, December 12th. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.80. The business had revenue of $0.25 million for the quarter. On average, analysts expect Edesa Biotech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Edesa Biotech Stock Up 2.8%

EDSA opened at $1.12 on Friday. The business has a fifty day moving average of $1.48 and a 200 day moving average of $1.99. Edesa Biotech has a 52-week low of $0.94 and a 52-week high of $4.49. The stock has a market cap of $9.33 million, a P/E ratio of -0.83 and a beta of 0.21.

Institutional Investors Weigh In On Edesa Biotech

A hedge fund recently bought a new stake in Edesa Biotech stock. Susquehanna International Group LLP bought a new position in Edesa Biotech, Inc. (NASDAQ:EDSA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 14,610 shares of the company’s stock, valued at approximately $36,000. Susquehanna International Group LLP owned approximately 0.21% of Edesa Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 5.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Edesa Biotech in a research report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Edesa Biotech in a report on Monday, November 3rd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Edesa Biotech has a consensus rating of “Hold” and an average target price of $5.00.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.